FDA
- Status: approved
🇺🇸 human papillomavirus vaccine, recombinant in United States
4 US adverse-event reports
Marketing authorisation
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 20 April 2025 – 20 April 2026
- Total reports: 4
Most-reported reactions
- Condition Aggravated — 1 report (25%)
- Drug Ineffective — 1 report (25%)
- Drug Intolerance — 1 report (25%)
- Off Label Use — 1 report (25%)
human papillomavirus vaccine, recombinant in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is human papillomavirus vaccine, recombinant approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for human papillomavirus vaccine, recombinant in United States?
Louisiana State University Health Sciences Center in New Orleans is the originator. The local marketing authorisation holder may differ — check the official source linked above.